Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
47
RAPT Quote, Financials, Valuation and Earnings
Last price:
$57.71
Seasonality move
:
-39.76%
Day range:
$57.71 - $57.82
52-week range:
$5.67 - $57.86
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
54.16x
P/B ratio:
6.28x
Volume:
12.1M
Avg. volume:
4.2M
1-year change:
506.3%
Market cap:
$954.6M
Revenue:
--
EPS (TTM):
-$10.51
Analysts' Opinion
-
Consensus RatingRapt Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $58.00, Rapt Therapeutics, Inc. has an estimated upside of 0.49% from its current price of $57.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $58.00 representing 100% downside risk from its current price of $57.72.
Fair Value
-
According to the consensus of 9 analysts, Rapt Therapeutics, Inc. has 0.49% upside to fair value with a price target of $58.00 per share.
RAPT vs. S&P 500
-
Over the past 5 trading days, Rapt Therapeutics, Inc. has overperformed the S&P 500 by 1.51% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rapt Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rapt Therapeutics, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Rapt Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Rapt Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Rapt Therapeutics, Inc. reported earnings per share of -$0.65.
Enterprise value:
799.8M
EV / Invested capital:
--
Price / LTM sales:
54.16x
EV / EBIT:
--
EV / Revenue:
3.48x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-9.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.9M
Return On Assets:
-59.99%
Net Income Margin (TTM):
--
Return On Equity:
-67.79%
Return On Invested Capital:
-66.16%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.4M | -$1.2M | -$3.9M | -$297K | -$200K | |
| Operating Income | -$118.3M | -$114.9M | -$112.6M | -$19.8M | -$19.4M | |
| EBITDA | -$114.9M | -$113.6M | -$108.7M | -$19.5M | -$19.2M | |
| Diluted EPS | -$2.89 | -$2.78 | -$10.51 | -$0.47 | -$0.65 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $214.5M | $197.9M | $187.1M | $102.6M | $161M | |
| Total Assets | $217.5M | $209.5M | $199.7M | $108.5M | $165.7M | |
| Current Liabilities | $12.7M | $13.9M | $21.8M | $10.4M | $13.4M | |
| Total Liabilities | $15.6M | $20.2M | $26.9M | $13M | $13.8M | |
| Total Equity | $201.9M | $189.3M | $172.8M | $95.5M | $152M | |
| Total Debt | -- | $6.3M | $5.1M | $2.6M | $387K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$92.1M | -$100.6M | -$86.6M | -$17.6M | -$12.5M | |
| Cash From Investing | $42.2M | $74.2M | -$56.7M | $18.4M | $8.5M | |
| Cash From Financing | $76.3M | $10.2M | $143.3M | -- | $36K | |
| Free Cash Flow | -$93.3M | -$100.8M | -$86.7M | -$17.6M | -$12.5M | |
RAPT
Sector
Market Cap
$954.6M
$24M
Price % of 52-Week High
99.76%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
-33.45%
-1.62%
1-Year Price Total Return
506.3%
-22.92%
Beta (5-Year)
0.468
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$57.74
200-day SMA
Buy
Level
$23.03
Bollinger Bands (100)
Buy
Level
24.96 - 46.88
Chaikin Money Flow
Sell
Level
-10.5M
20-day SMA
Buy
Level
$56.55
Relative Strength Index (RSI14)
Buy
Level
78.96
ADX Line
Buy
Level
42.5
Williams %R
Neutral
Level
-48.2759
50-day SMA
Buy
Level
$43.01
MACD (12, 26)
Buy
Level
15.57
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Sell
Level
-12.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.0337)
Sell
CA Score
(Annual)
Level (-1.9882)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.4172)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, RAPT has received 0 Buy ratings 9 Hold ratings, and 0 Sell ratings. The RAPT average analyst price target in the past 3 months is $58.00.
-
Where Will Rapt Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rapt Therapeutics, Inc. share price will rise to $58.00 per share over the next 12 months.
-
What Do Analysts Say About Rapt Therapeutics, Inc.?
Analysts are divided on their view about Rapt Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rapt Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $58.00.
-
What Is Rapt Therapeutics, Inc.'s Price Target?
The price target for Rapt Therapeutics, Inc. over the next 1-year time period is forecast to be $58.00 according to 9 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is RAPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rapt Therapeutics, Inc. is a Hold. 9 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RAPT?
You can purchase shares of Rapt Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rapt Therapeutics, Inc. shares.
-
What Is The Rapt Therapeutics, Inc. Share Price Today?
Rapt Therapeutics, Inc. was last trading at $57.71 per share. This represents the most recent stock quote for Rapt Therapeutics, Inc.. Yesterday, Rapt Therapeutics, Inc. closed at $57.72 per share.
-
How To Buy Rapt Therapeutics, Inc. Stock Online?
In order to purchase Rapt Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get RAPT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RAPT
Sector
P/E ratio
--
23.44x
PEG ratio
-0.02x
-0.01x
P/B ratio
6.28x
1.73x
Price / LTM sales
54.16x
1.51x
Growth Metrics
RAPT
Sector
Revenue growth
--
3.31%
Earnings growth
-37.61%
10.7%
Revenue (5-year growth)
--
6.28%
Earnings forecast
-$0.88
-$0.19
Profitability
RAPT
Sector
Profitability FY 2024
-$3.5M
$2.6M
Return on invested capital
-66.16%
-33.62%
Return on assets
-59.99%
-29.74%
Return on equity
-67.79%
-39.33%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
RAPT
Sector
Total cash
$157.3M
$25M
Short term investments
$61.3M
$23.9M
Total assets
$240.3M
$71.9M
Long term debt
$387K
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
